Interferons at age 50: past, current and future impact on biomedicine (original) (raw)

• Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond., B, Biol. Sci. 147, 258–267 (1957). Discovery of both induction and action.
  CAS PubMed Google Scholar
• Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783–801 (2006).
  CAS PubMed Google Scholar
• Field, A. K., Tytell, A. A., Lampson, G. P. & Hilleman, M. R. Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc. Natl Acad. Sci. USA 58, 1004–1010 (1967).
  CAS PubMed Google Scholar
• Sen, G. C. & Sarkar, S. N. Transcriptional signaling by double-stranded RNA: role of TLR3. Cytokine Growth Factor Rev. 16, 1–14 (2005).
  CAS PubMed Google Scholar
• Yoneyama, M. et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nature Immunol. 5, 730–737 (2004). Identification of specific cytoplasmic RNA helicases, recognizing viral RNAs, as important components of the innate immune system.
  CAS Google Scholar
• Tabeta, K. et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl Acad. Sci. USA 101, 3516–3521 (2004).
  CAS PubMed Google Scholar
• Kato, H. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101–105 (2006).
  CAS PubMed Google Scholar
• Gitlin, L. et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA 103, 8459–8464 (2006).
  CAS PubMed Google Scholar
• Le Goffic, R. et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog. 2, e53 (2006).
  PubMed Google Scholar
• Wang, T. et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nature Med. 10, 1366–1373 (2004).
  CAS PubMed Google Scholar
• Meylan, E. & Tschopp, J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol. Cell 22, 561–569 (2006).
  CAS PubMed Google Scholar
• Kawai, T. & Akira, S. Antiviral signaling through pattern recognition receptors. J. Biochem. (Tokyo)141, 137–145 (2007).
  CAS PubMed Google Scholar
• Yoneyama, M. & Fujita, T. Cytoplasmic double-stranded DNA sensor. Nature Immunol. 8, 907–908 (2007).
  CAS Google Scholar
• Panne, D., Maniatis, T. & Harrison, S. C. An atomic model of the interferon-β enhanceosome. Cell 129, 1111–1123 (2007).
  CAS PubMed PubMed Central Google Scholar
• Honda, K., Takaoka, A. & Taniguchi, T. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 25, 349–360 (2006).
  CAS PubMed Google Scholar
• Tenoever, B. R. et al. Multiple functions of the IKK-related kinase IKKɛ in interferon-mediated antiviral immunity. Science 315, 1274–1278 (2007).
  CAS PubMed Google Scholar
• Fitzgerald, K. A. et al. IKKɛ and TBK1 are essential components of the IRF3 signaling pathway. Nature Immunol. 4, 491–496 (2003). Indentification of specific protein kinases, which are distantly related to the more well-known IKK kinases, to be essential for IRF3 activation in response to many microbial products.
  CAS Google Scholar
• Biron, C. A. & Sen, G. C. in Fields Virology (eds Knipe, D. M. et al.) 249–278 (Lippincott, Williams & Wilkins, Philadelphia, 2006).
  Google Scholar
• Hiscott, J., Nguyen, T-L. A., Arguello, M., Nakhaei, P. & Paz, S. Manipulation of the nuclear factor-κB pathway and the innate immune response by viruses. Oncogene 25, 6844–6867 (2006).
  CAS PubMed Google Scholar
• Foy, E. et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl Acad. Sci. USA 102, 2986–2991 (2005).
  CAS PubMed Google Scholar
• Garcia-Sastre, A. & Biron, C. A. Type 1 interferons and the virus–host relationship: a lesson in detente. Science 312, 879–882 (2006).
  CAS PubMed Google Scholar
• Finlay, B. B. & McFadden, G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124, 767–782 (2006).
  CAS PubMed Google Scholar
• Pichlmair, A. et al. RIG-I mediated antiviral responses to single-stranded RNA bearing 5′ phosphates. Science 314, 997–1001 (2006).
  CAS Google Scholar
• Casrouge, A. et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 314, 308–312 (2006).
  CAS PubMed Google Scholar
• Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740–745 (2000).
  CAS PubMed Google Scholar
• Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol. 3, 196–200 (2002).
  CAS Google Scholar
• Roberts, Z. J. et al. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J. Exp. Med. 204, 1559–1569 (2007).
  CAS PubMed PubMed Central Google Scholar
• O'Neill, L. A. Targeting signal transduction as a strategy to treat inflammatory diseases. Nature Rev. Drug Discov. 5, 549–563 (2006).
  CAS Google Scholar
• Krieg, A. M. Therapeutic potential of Toll-like receptor 9 activation. Nature Rev. Drug Discov. 5, 471–484 (2006).
  CAS Google Scholar
• Havell, E. A. et al. Two antigenically distinct species of human interferon. Proc. Natl Acad. Sci. USA 72, 2185–2187 (1975).
  CAS PubMed Google Scholar
• Streuli, M., Nagata, S. & Weissmann, C. At least three human type α-interferons: structure of α 2. Science 209, 1343–1347 (1980).
  CAS PubMed Google Scholar
• Taniguchi, T. et al. Human leukocyte and fibroblast interferons are structurally related. Nature 285, 547–549 (1980).
  CAS PubMed Google Scholar
• Goeddel, D. V. et al. The structure of eight distinct cloned human leukocyte interferon cDNAs. Nature 290, 20–26 (1981).
  CAS PubMed Google Scholar
• Pestka, S., Krause, C. D. & Walter, R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8–32 (1998).
  Google Scholar
• Hardy, M. P., Owczarek, C. M., Jermiin, L. S., Ejdeback, M. & Hertzog, P. J. Characterization of the type I interferon locus and identification of novel genes. Genomics 84, 331–345 (2004).
  CAS PubMed Google Scholar
• Coelho, L. F., de Freitas Almeida, G. M., Mennechet, F. J., Blangy, A. & Uze, G. Interferon-α and -β differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc. Natl Acad. Sci. USA 102, 11917–11922 (2005).
  PubMed Google Scholar
• Foster, G. R. et al. IFN-α subtypes differentially affect human T cell motility. J. Immunol. 173, 1663–1670 (2004).
  CAS PubMed Google Scholar
• Hilkens, C. M., Schlaak, J. F. & Kerr, I. M. Differential responses to IFN-α subtypes in human T cells and dendritic cells. J. Immunol. 171, 5255–5263 (2003).
  CAS PubMed Google Scholar
• Uze, G., Schreiber, G., Piehler, J. & Pellegrini, S. The receptor of the type I interferon family. Cur. Topics Microbiol. Immunol. 316, 71–95 (2007).
  CAS Google Scholar
• Walker, J. & Tough, D. F. Modification of TLR-induced activation of human dendritic cells by type I IFN: synergistic interaction with TLR4 but not TLR3 agonists. Eur. J. Immunol. 36, 1827–1836 (2006).
  CAS PubMed Google Scholar
• Roberts, R. M., Liu, L. & Alexenko, A. New and atypical families of type I interferons in mammals: comparative functions, structures, and evolutionary relationships. Prog. Nucleic Acid Res. Mol. Biol. 56, 287–325 (1997).
  CAS PubMed Google Scholar
• LaFleur, D. W. et al. Interferon-κ, a novel type I interferon expressed in human keratinocytes. J. Biol. Chem. 276, 39765–39771 (2001).
  CAS PubMed Google Scholar
• Coccia, E. M. et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 34, 796–805 (2004).
  CAS PubMed Google Scholar
• Mitsui, Y. & Senda, T. Elucidation of the basic three-dimensional structure of type I interferons and its functional and evolutionary implications. J. Interferon Cytokine Res. 17, 319–326 (1997).
  CAS PubMed Google Scholar
• Gavutis, M., Jaks, E., Lamken, P. & Piehler, J. Determination of the two-dimensional interaction rate constants of a cytokine receptor complex. Biophys. J. 90, 3345–3355 (2006).
  CAS PubMed PubMed Central Google Scholar
• Jaitin, D. A. et al. Inquiring into the differential action of interferons (IFNs): an IFN-α2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-β. Mol. Cell Biol. 26, 1888–1897 (2006). Identification of the structural effects that lead to the differential activities of α and β IFNs. The bioactivity profile of a given type I IFN subtype is shown to be related to the stability of its complex with the receptor, and not some other structural feature.
  CAS PubMed PubMed Central Google Scholar
• Jaks, E., Gavutis, M., Uze, G., Martal, J. & Piehler, J. Differential receptor subunit affinities of type I interferons govern differential signal activation. J. Mol. Biol. 366, 525–539 (2007).
  CAS PubMed Google Scholar
• Kalie, E., Jaitin, D. A., Abramovich, R. & Schreiber, G. An interferon α2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J. Biol. Chem. 282, 11602–11611 (2007).
  CAS PubMed Google Scholar
• Severa, M. et al. Differential responsiveness to IFN-α and IFN-β of human mature DC through modulation of IFNAR expression. J. Leukoc. Biol. 79, 1286–1294 (2006).
  CAS PubMed Google Scholar
• Frodsham, A. J. et al. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc. Natl Acad. Sci. USA 103, 9148–9153 (2006).
  CAS PubMed Google Scholar
• Bach, E. A., Aguet, M. & Schreiber, R. D. The IFN γ receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15, 563–591 (1997).
  CAS PubMed Google Scholar
• Kotenko, S. V. & Langer, J. A. Full house: 12 receptors for 27 cytokines. Int. Immunopharmacol. 4, 593–608 (2004).
  CAS PubMed Google Scholar
• Roesler, J. et al. Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-γ-receptor (IFN-γR1) deficiency: mutational analysis and evaluation of therapeutic options. Exp. Hematol. 27, 1368–1374 (1999).
  CAS PubMed Google Scholar
• Uze, G. & Monneron, D. IL-28 and IL-29: newcomers to the interferon family. Biochimie 89, 729–734 (2007).
  CAS PubMed Google Scholar
• Zinn, K., DiMaio, D. & Maniatis, T. Identification of two distinct regulatory regions adjacent to the human β-interferon gene. Cell 34, 865–879 (1983).
  CAS PubMed Google Scholar
• Merlin, G., Chebath, J., Benech, P., Metz, R. & Revel, M. Molecular cloning and sequence of partial cDNA for interferon-induced (2′-5′)oligo(A) synthetase mRNA from human cells. Proc. Natl Acad. Sci. USA 80, 4904–4908 (1983).
  CAS PubMed Google Scholar
• Friedman, R. L., Manly, S. P., McMahon, M., Kerr, I. M. & Stark, G. R. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell 38, 745–755 (1984).
  CAS PubMed Google Scholar
• Friedman, R. L. & Stark, G. R. α-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences. Nature 314, 637–639 (1985).
  CAS PubMed Google Scholar
• Fu, X. Y., Schindler, C., Improta, T., Aebersold, R. & Darnell, J. E. Jr. The proteins of ISGF-3, the interferon α-induced transcriptional activator, define a gene family involved in signal transduction. Proc. Natl Acad. Sci. USA 89, 7840–7843 (1992). Identification of the transcription factors (STATs and IRFs) required for the response to type I IFNs.
  CAS PubMed Google Scholar
• Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H. & Schreiber, R. D. How cells respond to interferons. Annu. Rev. Biochem. 67, 227–264 (1998).
  CAS PubMed Google Scholar
• Schindler, C., Levy, D. E. & Decker, T. JAK–STAT signaling: from interferons to cytokines. J. Biol. Chem. 282, 20059–20063 (2007).
  CAS PubMed Google Scholar
• Velazquez, L., Fellous, M., Stark, G. R. & Pellegrini, S. A protein tyrosine kinase in the interferon α/β signaling pathway. Cell 70, 313–322 (1992). This paper identifies a JAK family member that is necessary for the IFN response, thus showing how type I IFN stimulates the phosphorylation of tyrosine residues in the receptor and the STATs.
  CAS PubMed Google Scholar
• Qing, Y. & Stark, G. R. Alternative activation of STAT1 and STAT3 in response to interferon-γ. J. Biol. Chem. 279, 41679–41685 (2004).
  CAS PubMed Google Scholar
• van Boxel-Dezaire, A. H., Rani, M. R. & Stark, G. R. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25, 361–372 (2006).
  CAS PubMed Google Scholar
• van Boxel-Dezaire, A. H. & Stark, G. R. Cell type-specific signaling in response to interferon-γ. Curr. Top. Microbiol. Immunol. 316, 119–154 (2007).
  CAS PubMed Google Scholar
• Jouanguy, E. et al. Human primary immunodeficiencies of type I interferons. Biochimie 89, 878–883 (2007).
  CAS PubMed Google Scholar
• Rani, M. R., Hibbert, L., Sizemore, N., Stark, G. R. & Ransohoff, R. M. Requirement of phosphoinositide 3-kinase and Akt for interferon-β-mediated induction of the β-R1 (SCYB11) gene. J. Biol. Chem. 277, 38456–38461 (2002).
  CAS PubMed Google Scholar
• Rani, M. R. & Ransohoff, R. M. Alternative and accessory pathways in the regulation of IFN-β-mediated gene expression. J. Interferon Cytokine Res. 25, 788–798 (2005).
  CAS PubMed Google Scholar
• Hilkens, C. M., Schlaak, J. F. & Kerr, I. M. Differential responses to IFN-α subtypes in human T cells and dendritic cells. J. Immunol. 171, 5255–5263 (2003).
  CAS PubMed Google Scholar
• Platanias, L. C. Mechanisms of type-I- and type-II- interferon-mediated signaling. Nature Rev. Immunol. 5, 375–386 (2005).
  CAS Google Scholar
• Alexander, W. S. & Hilton, D. J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 22, 503–529 (2004).
  CAS PubMed Google Scholar
• Yi, T. et al. Anticancer activity of sodium stibogluconate in synergy with IFNs. J. Immunol. 169, 5978–5985 (2002).
  CAS PubMed Google Scholar
• Ho, H. H. & Ivashkiv, L. B. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J. Biol. Chem. 281, 14111–14118 (2006).
  CAS PubMed Google Scholar
• Hu, X. et al. Sensitization of IFN-γ Jak–STAT signaling during macrophage activation. Nature Immunol. 3, 859–866 (2002).
  CAS Google Scholar
• Kirkwood, J. et al. Modulation of STAT1 and STAT3 signaling in melanoma by high-dose IFN-α2b. Clin. Cancer Res. 13, 1523–1531 (2007).
  PubMed Google Scholar
• Kumar, A., Commane, M., Flickinger, T. W., Horvath, C. M. & Stark, G. R. Defective TNF-α-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278, 1630–1632 (1997).
  CAS PubMed Google Scholar
• Yang, J. et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 65, 939–947 (2005).
  CAS PubMed Google Scholar
• Yang, J. et al. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκB. Genes Dev. 21, 1396–1408 (2007).
  CAS PubMed PubMed Central Google Scholar
• Der, S. D., Zhou, A., Williams, B. R. & Silverman, R. H. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95, 15623–15628 (1998).
  CAS PubMed Google Scholar
• de Veer, M. J. et al. Functional classification of interferon-stimulated genes identified using microarrays. J. Leukoc. Biol. 69, 912–920 (2001).
  CAS PubMed Google Scholar
• Silverman, R. H. Viral encounters with OAS and RNase L during the interferon antiviral response. J. Virol. 5 Sep 2007 (doi:10.1128/JVI.01471-07).
  CAS PubMed PubMed Central Google Scholar
• Kerr, I. M. & Brown, R. E. pppA2′p5′A2′p5′A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc. Natl Acad. Sci. USA 75, 256–260 (1978).
  CAS PubMed Google Scholar
• Zhou, A., Hassel, B. A. & Silverman, R. H. Expression cloning of 2–5A-dependent RNAase: a uniquely regulated mediator of interferon action. Cell 72, 753–765 (1993).
  CAS PubMed Google Scholar
• Dong, B. & Silverman, R. H. 2–5A-dependent RNase molecules dimerize during activation by 2-5A. J. Biol. Chem. 270, 4133–4137 (1995).
  CAS PubMed Google Scholar
• Wreschner, D. H., McCauley, J. W., Skehel, J. J. & Kerr, I. M. Interferon action — sequence specificity of the ppp(A2′p)nA-dependent ribonuclease. Nature 289, 414–417 (1981).
  CAS PubMed Google Scholar
• Floyd-Smith, G., Slattery, E. & Lengyel, P. Interferon action: RNA cleavage pattern of a (2′-5′)oligoadenylate-dependent endonuclease. Science 212, 1030–1032 (1981).
  CAS PubMed Google Scholar
• Zhou, A. et al. Interferon action and apoptosis are defective in mice devoid of 2′, 5′-oligoadenylate-dependent RNase, L. EMBO J. 16, 6355–6363 (1997).
  CAS PubMed PubMed Central Google Scholar
• Castelli, J. C. et al. The role of 2′-5′ oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ. 5, 313–320 (1998).
  CAS PubMed Google Scholar
• Castelli, J. C. et al. A study of the interferon antiviral mechanism: apoptosis activation by the 2–5A system. J. Exp. Med. 186, 967–972 (1997).
  CAS PubMed PubMed Central Google Scholar
• Malathi, K., Dong, B., Gale, M. Jr, Silverman, R. H. Small self RNA generates by RNase L amplifies antiviral innate immunity. Nature 448, 816–819 (2007).
  CAS PubMed PubMed Central Google Scholar
• Thakur, C. S. et al. Small-molecule activators of RNase L with broad-spectrum antiviral activity. Proc. Natl Acad. Sci. USA 104, 9585–9590 (2007).
  CAS PubMed Google Scholar
• Roberts, W. K., Hovanessian, A. Brown, R. E., Clemens, M. J. & Kerr, I. M. Interferon-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis. Nature 264, 477–480 (1976).
  CAS PubMed Google Scholar
• Zilberstein, A., Kimchi, A., Schmidt, A. & Revel, M. Isolation of two interferon-induced translational inhibitors: a protein kinase and an oligo-isoadenylate synthetase. Proc. Natl Acad. Sci. USA 75, 4734–4738 (1978).
  CAS PubMed Google Scholar
• Meurs, E. et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 62, 379–390 (1990).
  CAS PubMed Google Scholar
• Williams, B. R. Signal integration via PKR. Sci STKE 89, RE2 (2001).
  Google Scholar
• Williams, B. R. PKR; a sentinel kinase for cellular stress. Oncogene 18, 6112–6120 (1999).
  CAS PubMed Google Scholar
• Patel, R. C. & Sen, G. C. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J. 17, 4379–4390 (1998).
  CAS PubMed PubMed Central Google Scholar
• Gale, M. Jr. & Katze, M. G. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol. Ther. 78, 29–46 (1998).
  CAS PubMed Google Scholar
• Sarkar, S. N. & Sen, G. C. Novel functions of proteins encoded by viral stress-inducible genes. Pharmacol. Ther. 103, 245–259 (2004).
  CAS PubMed Google Scholar
• Wang, C. et al. α Interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J. Virol. 77, 3898–3912 (2003).
  CAS PubMed PubMed Central Google Scholar
• Lindenmann, J. Inheritance of resistance to influenza virus in mice. Proc. Soc. Exp. Biol. Med. 116, 506–509 (1964).
  CAS PubMed Google Scholar
• Horisberger, M. A., Staeheli, P. & Haller, O. Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus. Proc. Natl Acad. Sci. USA 80, 1910–1914 (1983).
  CAS PubMed Google Scholar
• Staeheli, P., Haller, O., Boll, W., Lindenmann, J. & Weissmann, C. Mx protein: constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to influenza virus. Cell 44, 147–158 (1986).
  CAS PubMed Google Scholar
• Haller, O., Staeheli, P. & Kochs, G. Interferon-induced Mx proteins in antiviral host defense. Biochimie 89, 812–818 (2007).
  CAS PubMed Google Scholar
• Recht, M., Borden, E. C. & Knight, E. Jr. A human 15-kDa IFN-induced protein induces the secretion of IFN-γ. J. Immunol. 147, 2617–2623 (1991).
  CAS PubMed Google Scholar
• D'Cunha, J. et al. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J. Immunol. 157, 4100–4108 (1996).
  CAS PubMed Google Scholar
• Andersen, J. B. & Hassel, B. A. The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: friend or foe? Cytokine Growth Factor Rev. 17, 411–421 (2006).
  CAS PubMed Google Scholar
• Okumura, A., Lu, G., Pitha-Rowe, I. & Pitha, P. M. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc. Natl Acad. Sci. USA 103, 1440–1445 (2006).
  CAS PubMed Google Scholar
• Lenschow, D. J. et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl Acad. Sci. USA 104, 1371–1376 (2007).
  CAS PubMed Google Scholar
• Zhou, Q. et al. Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids. J. Biol. Chem. 272, 18240–18244 (1997).
  CAS PubMed Google Scholar
• Ben-Efraim, I., Zhou, Q., Wiedmer, T., Gerace, L. & Sims, P. J. Phospholipid scramblase 1 is imported into the nucleus by a receptor-mediated pathway and interacts with DNA. Biochemistry 43, 3518–3526 (2004).
  CAS PubMed Google Scholar
• Dong, B. et al. Phospholipid scramblase 1 potentiates the antiviral activity of interferon. J. Virol. 78, 8983–8993 (2004).
  CAS PubMed PubMed Central Google Scholar
• Kayagaki, N. et al. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189, 1451–1460 (1999).
  CAS PubMed PubMed Central Google Scholar
• Chawla-Sarkar, M., Leaman, D. W. & Borden, E. C. Preferential induction of apoptosis by interferon (IFN)-β compared with IFN-α2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin. Cancer. Res. 7, 1821–1831 (2001).
  CAS PubMed Google Scholar
• Chen, Q. et al. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 98, 2183–2192 (2001).
  CAS PubMed PubMed Central Google Scholar
• Kelly, J. M. et al. Characterization of a human gene inducible by α- and β-interferons and its expression in mouse cells. EMBO J. 5, 1601–1606 (1986).
  CAS PubMed PubMed Central Google Scholar
• Martensen, P. M. & Justesen, J. Small ISGs coming forward. J. Interferon Cytokine Res. 24, 1–19 (2004).
  CAS PubMed Google Scholar
• Tahara, E. Jr. et al. G1P3, an interferon inducible gene 6–16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell. Cancer Immunol. Immunother. 54, 729–740 (2005).
  CAS PubMed Google Scholar
• Martensen, P. M. et al. The interferon α induced protein ISG12 is localized to the nuclear membrane. Eur. J. Biochem. 268, 5947–5954 (2001).
  CAS PubMed Google Scholar
• Labrada, L., Liang, X. H., Zheng, W., Johnston, C. & Levine, B. Age-dependent resistance to lethal alphavirus encephalitis in mice: analysis of gene expression in the central nervous system and identification of a novel interferon-inducible protective gene, mouse ISG12. J. Virol. 76, 11688–11703 (2002).
  CAS PubMed PubMed Central Google Scholar
• Anderson, S. L., Carton, J. M., Lou, J., Xing, L. & Rubin, B. Y. Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus. Virology 256, 8–14 (1999).
  CAS PubMed Google Scholar
• Espert, L. et al. ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses. J. Biol. Chem. 278, 16151–16158 (2003).
  CAS PubMed Google Scholar
• Regad, T. et al. PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J. 20, 3495–3505 (2001).
  CAS PubMed PubMed Central Google Scholar
• Liu, Y., George, C. X., Patterson, J. B. & Samuel, C. E. Functionally distinct double-stranded RNA-binding domains associated with alternative splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase. J. Biol. Chem. 272, 4419–4428 (1997).
  CAS PubMed Google Scholar
• Chin, K. C. & Cresswell, P. Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus. Proc. Natl Acad. Sci. USA 98, 15125–15130 (2001).
  CAS PubMed Google Scholar
• Melkova, Z. & Esteban, M. Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. J. Immunol. 155, 5711–5718 (1995).
  CAS PubMed Google Scholar
• Enninga, J., Levy, D. E., Blobel, G. & Fontoura, B. M. Role of nucleoporin induction in releasing an mRNA nuclear export block. Science 295, 1523–1525 (2002).
  CAS PubMed Google Scholar
• Samuel CE Antiviral actions of interferons. Clin. Microbiol. Rev. 14, 778–809 (2001).
  CAS PubMed PubMed Central Google Scholar
• Siegal, F. P. et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284, 1835–1837 (1999).
  CAS PubMed Google Scholar
• Zhao, W., Cha, E. N., Lee, C., Park, C. Y. & Schindler, C. Stat2-dependent regulation of MHC class II expression. J. Immunol. 179, 463–471 (2007).
  CAS PubMed Google Scholar
• Cresswell, P. Intracellular surveillance: controlling the assembly of MHC class I-peptide complexes. Traffic 1, 301–305 (2000). A review of the roles of constitutive and IFN-inducible components in MHC class I-peptide complex assembly.
  CAS PubMed Google Scholar
• Drozina, G., Kohoutek, J., Jabrane-Ferrat, N. & Peterlin, B. M. Expression of MHC II genes. Curr. Top. Microbiol. Immunol. 290, 147–170 (2005).
  CAS PubMed Google Scholar
• Fruh, K. & Yang, Y. Antigen presentation by MHC class I and its regulation by interferon γ. Curr. Opin. Immunol. 11, 76–81 (1999).
  CAS PubMed Google Scholar
• Gaczynska, M., Rock, K. L. & Goldberg, A. L. γ-Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 365, 264–267 (1993).
  CAS PubMed Google Scholar
• Groothuis, T. & Neefjes, J. The ins and outs of intracellular peptides and antigen presentation by MHC class I molecules. Curr. Top. Microbiol. Immunol. 300, 127–148 (2005).
  CAS PubMed Google Scholar
• Cole, K. E. et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J. Exp. Med. 187, 2009–2021 (1998).
  CAS PubMed PubMed Central Google Scholar
• Farber, J. M. A macrophage mRNA selectively induced by γ-interferon encodes a member of the platelet factor 4 family of cytokines. Proc. Natl Acad. Sci. USA 87, 5238–5242 (1990).
  CAS PubMed Google Scholar
• Rani, M. R. et al. Characterization of β-R1, a gene that is selectively induced by interferon β (IFN-β) compared with IFN-α. J. Biol. Chem. 271, 22878–22884 (1996).
  CAS PubMed Google Scholar
• Luster, A. D., Unkeless, J. C. & Ravetch, J. V. γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315, 672–676 (1985).
  CAS PubMed Google Scholar
• Shi, F. D. & Van, K. L. Reciprocal regulation between natural killer cells and autoreactive T cells. Nature Rev. Immunol. 6, 751–760 (2006).
  CAS Google Scholar
• Fontes, J. D., Kanazawa, S., Nekrep, N. & Peterlin, B. M. The class II transactivator CIITA is a transcriptional integrator. Microbes Infect. 1, 863–869 (1999).
  CAS PubMed Google Scholar
• LeibundGut-Landmann, S. et al. Specificity and expression of CIITA, the master regulator of MHC class II genes. Eur. J. Immunol. 34, 1513–1525 (2004).
  CAS PubMed Google Scholar
• Wright, K. L. & Ting, J. P. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol. 27, 405–412 (2006). A review of the regulation of MHC class II genes, the IFN-inducible factor CIITA, chromatin modification and constitutive transcription factors.
  CAS PubMed Google Scholar
• Denzin, L. K., Hammond, C. & Cresswell, P. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J. Exp. Med. 184, 2153–2165 (1996).
  CAS PubMed PubMed Central Google Scholar
• Denzin, L. K., Robbins, N. F., Carboy-Newcomb, C. & Cresswell, P. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity 1, 595–606 (1994).
  CAS PubMed Google Scholar
• Gruneberg, U. et al. The structure and function of the novel MHC class II molecule, HLA-DM. Biochem. Soc. Trans. 25, 208S (1997).
  CAS Google Scholar
• Kropshofer, H., Arndt, S. O., Moldenhauer, G., Hammerling, G. J. & Vogt, A. B. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 6, 293–302 (1997).
  CAS PubMed Google Scholar
• Morris, P. et al. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 368, 551–554 (1994).
  CAS PubMed Google Scholar
• Vogt, A. B. & Kropshofer, H. HLA-DM — an endosomal and lysosomal chaperone for the immune system. Trends Biochem. Sci. 24, 150–154 (1999).
  CAS PubMed Google Scholar
• Kleinschmidt, W. J. & Schultz, R. M. Similarities of murine γ interferon and the lymphokine that renders macrophages cytotoxic. J. Interferon Res. 2, 291–299 (1982).
  CAS PubMed Google Scholar
• Blumberg, B. S. Australia antigen and the biology of hepatitis B. Science 197, 17–25 (1977).
  CAS PubMed Google Scholar
• Greenberg, H. B. et al. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N. Engl. J. Med. 295, 517–522 (1976).
  CAS PubMed Google Scholar
• Weimar, W. et al. Fibroblast interferon in HBsAg-positive chronic active hepatitis. Lancet 310, 1282 (1977).
  Google Scholar
• Hoofnagle, J. H. et al. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology 95, 1318–1325 (1988).
  CAS PubMed Google Scholar
• Lok, A. S. & McMahon, B. J. Chronic hepatitis B. Hepatology 45, 507–539 (2007).
  CAS PubMed Google Scholar
• Bertoletti, A., Maini, M. & Williams, R. Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res. 60, 61–66 (2003).
  CAS PubMed Google Scholar
• Carmen, W. et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic HBV infection. Lancet 2, 588–591 (1989).
  Google Scholar
• Lau, G. K. et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352, 2682–2695 (2005).
  CAS PubMed Google Scholar
• Marcellin, P. et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351, 1206–1217 (2004).
  CAS PubMed Google Scholar
• Hoofnagle, J., Mullen, K. & Jones, D. Treatment of chronic nonA nonB hepatitis with recombinant human α interferon: a preliminary report. N. Engl. J. Med. 328, 465–470 (1986).
  Google Scholar
• Choo, Q.-L. et al. Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis clone. Science 244, 359–361 (1989).
  CAS PubMed Google Scholar
• Heathcote, J. & Main, J. Treatment of hepatitis C. J. Viral Hepat. 12, 223–235 (2005).
  CAS PubMed Google Scholar
• Foster, G. R. Past, present, and future hepatitis C treatments. Semin. Liver Dis. 24 (Suppl. 2), 97–104 (2004).
  CAS PubMed Google Scholar
• de Koning, E. W., van Bijsterveld, O. P. & Cantell, K. Combination therapy for dendritic keratitis with acyclovir and α-interferon. Arch. Ophthalmol. 101, 1866–1868 (1983).
  CAS PubMed Google Scholar
• Jones, B. R., Coster, D. J., Falcon, M. G. & Cantell, K. Topical therapy of ulcerative herpetic keratitis with human interferon. Lancet 17, 128 (1976).
  Google Scholar
• Merigan, T. C. et al. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N. Engl. J. Med. 298, 981–987 (1978).
  CAS PubMed Google Scholar
• Pazin, G. J. et al. Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. N. Engl. J. Med. 301, 225–230 (1979).
  CAS PubMed Google Scholar
• Winston, D. J. et al. Recombinant interferon α-2a for treatment of herpes zoster in immunosuppressed patients with cancer. Am. J. Med. 85, 147–151 (1988).
  CAS PubMed Google Scholar
• Lui, S. F. et al. Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. Nephrol. Dial. Transplant. 7, 1230–1237 (1992).
  CAS PubMed Google Scholar
• Haglund, S., Lundquist, P. G., Cantell, K. & Strander, H. Interferon therapy in juvenile laryngeal papillomatosis. Arch. Otolaryngol. 107, 327–332 (1981).
  CAS PubMed Google Scholar
• Pazin, G. J. et al. Effects of interferon-α on human warts. J. Interferon Res. 2, 235–243 (1982).
  CAS PubMed Google Scholar
• Eron, L. J. et al. Interferon therapy for condylomata acuminata. N. Engl. J. Med. 315, 1059–1064 (1986).
  CAS PubMed Google Scholar
• Healy, G. B. et al. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N. Engl. J. Med. 319, 401–407 (1988). Demonstrates clinical effect for these HPV-related neoplasms, with implications for treatment of HPV-related upper respiratory malignancies.
  CAS PubMed Google Scholar
• Weck, P. K., Buddin, D. A. & Whisnant, J. K. Interferons in the treatment of genital human papillomavirus infections. Am. J. Med. 85, 159–164 (1988).
  CAS PubMed Google Scholar
• Deuñas, L. et al. Use of interferon-α in laryngeal papillomatosis: eight years of the Cuban national programme. J. Laryngol. Otol. 111, 134–140 (1997).
  PubMed Google Scholar
• Beutner, K. R. et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob. Agents Chemother. 42, 789–794 (1998).
  CAS PubMed PubMed Central Google Scholar
• Tyring, S. K. et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J. Infect. Dis. 178, 551–555 (1998).
  CAS PubMed Google Scholar
• Moore, R. A., Edwards, J. E., Hopwood, J. & Hicks, D. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect. Dis. 1, e3 (2001).
  Google Scholar
• Lane, H. C. et al. Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann. Intern. Med. 112, 805–811 (1990).
  CAS PubMed Google Scholar
• Krown, S. E., Aeppli, D. & Balfour, H. H. Jr. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-α2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91–253 Study Team. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20, 245–254 (1999).
  CAS PubMed Google Scholar
• Merigan, T. C., Reed, S. E., Hall, T. S. & Tyrrell, D. A. Inhibition of respiratory virus infection by locally applied interferon. Lancet 301, 563–567 (1973).
  Google Scholar
• Scott, G. M. et al. Prevention of rhinovirus colds by human interferon α-2 from Escherichia coli. Lancet 320, 186–188 (1982).
  Google Scholar
• Higgins, P. G. et al. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob. Agents Chemother. 24, 713–715 (1983).
  CAS PubMed PubMed Central Google Scholar
• Treanor, J. J., Betts, R. F., Erb, S. M., Roth, F. K. & Dolin, R. Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans. J. Infect. Dis. 156, 379–383 (1987).
  CAS PubMed Google Scholar
• Hayden, F. G., Kaiser, D. L. & Albrecht, J. K. Intranasal recombinant α-2b interferon treatment of naturally occurring common colds. Antimicrob. Agents Chemother. 32, 224–230 (1988).
  CAS PubMed PubMed Central Google Scholar
• Douglas, R. M. et al. Prophylactic efficacy of intranasal α 2-interferon against rhinovirus infections in the family setting. N. Engl. J. Med. 314, 65–70 (1986). Discusses whether a better-tolerated IFN or inducer can be identified.
  CAS PubMed Google Scholar
• Farr, B. M., Gwaltney, J. M. Jr., Adams, K. F. & Hayden, F. G. Intranasal interferon-α 2 for prevention of natural rhinovirus colds. Antimicrob. Agents Chemother. 6, 31–34 (1984).
  Google Scholar
• Loutfy, M. R. et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290, 3222–3228 (2003).
  CAS PubMed Google Scholar
• Jacobs, L., O'Malley, J., Freeman, A. & Ekes, R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 214, 1026–1028 (1981). A study using intrathecal natural IFN-β, showing a potent reduction in relapse rate. This galvanized the development of recombinant IFN-β for MS.
  CAS PubMed Google Scholar
• Knobler, R. L. et al. Systemic α-interferon therapy of multiple sclerosis. Neurology 34, 1273–1279 (1984).
  CAS PubMed Google Scholar
• Panitch, H. S., Hirsch, R. L., Haley, A. S. & Johnson, K. P. Exacerbations of multiple sclerosis in patients treated with γ interferon. Lancet 329, 893–895 (1987).
  Google Scholar
• Panitch, H. S., Hirsch, R. L., Schindler, J. & Johnson, K. P. Treatment of multiple sclerosis with γ interferon: exacerbations associated with activation of the immune system. Neurology 37, 1097–1102 (1987).
  CAS PubMed Google Scholar
• IFNB MS Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655–661 (1993).
• Paty, D. W. & Li, D. K. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43, 662–667 (1993). The first report showing that systemic recombinant IFN-β could modify the natural history of MS and that this effect could be documented using MRI.
  CAS PubMed Google Scholar
• Bermel, R. A. & Rudick, R. A. Interferon-β treatment for multiple sclerosis. Neurotherapeutics 4, 633–646 (2007).
  CAS PubMed Google Scholar
• Rudick, R. A. & Cutter, G. Interferon-β for multiple sclerosis: long-term benefits? Ann. Neurol. 61, 283–285 (2007). This review describes studies that, after almost 15 years of use, strongly suggested that IFN-β treatment might be efficacious in the way that investigators had hoped: to delay or preclude the onset of progressive MS.
  PubMed Google Scholar
• Hauser, S. L. & Johnston, S. C. Recombinant therapeutics: from bench to bedside (if your health plan concurs). Ann. Neurol. 60, 10A–11A (2006).
  PubMed Google Scholar
• Ascherio, A. & Munger, K. L. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann. Neurol. 61, 504–513 (2007). MS risk is a composite of genetics and environment. This review summarizes the noninfectious environmental component.
  CAS PubMed Google Scholar
• Ascherio, A. & Munger, K. L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 61, 288–299 (2007). This review summarizes the infectious environmental component.
  PubMed Google Scholar
• Lincoln, M. R. et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nature Genet. 37, 1108–1112 (2005). This report established that the MHC association, by a wide margin the strongest genetic susceptibility trait, resided in the HLA class II region.
  CAS PubMed Google Scholar
• Peltonen, L. Old suspects found guilty — the first genome profile of multiple sclerosis. N. Engl. J. Med. 357, 927–929 (2007).
  CAS PubMed Google Scholar
• Calabresi, P. A. et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann. Neurol. 41, 669–674 (1997).
  CAS PubMed Google Scholar
• Frank, J. A. et al. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann. Neurol. 36, S86–S90 (1994).
  PubMed Google Scholar
• Stone, L. A. et al. The effect of interferon-β on blood–brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann. Neurol. 37, 611–619 (1995). This report showed that the predominant therapeutic effect of IFN-β was to suppress new contrast-enhancing MRI lesions.
  CAS PubMed Google Scholar
• Shiow, L. R. et al. CD69 acts downstream of interferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440, 540–544 (2006).
  CAS PubMed Google Scholar
• Stuve, O. et al. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40, 853–863 (1996).
  CAS PubMed Google Scholar
• Leppert, D., Waubant, E., Burk, M. R., Oksenberg, J. R. & Hauser, S. L. Interferon β-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40, 846–852 (1996).
  CAS PubMed Google Scholar
• Fernald, G. H. et al. Genome-wide network analysis reveals the global properties of IFN-β immediate transcriptional effects in humans. J. Immunol. 178, 5076–5085 (2007).
  CAS PubMed Google Scholar
• Rudick, R. A., Lee, J. C., Simon, J., Ransohoff, R. M. & Fisher, E. Defining interferon β response status in multiple sclerosis patients. Ann. Neurol. 56, 548–555 (2004).
  CAS PubMed Google Scholar
• Gutterman, J. U. Cytokine therapeutics: lessons from interferon α. Proc. Natl Acad. Sci. USA 91, 1198–1205 (1994). A review of how IFNs were developed and their importance as a prototype for other biologicals as antitumour therapeutics.
  CAS PubMed Google Scholar
• Kurzrock, R., Talpaz, M. & Gutterman, J. U. Hairy cell leukemia: review of treatment. Br. J. Haematol. 79 (Suppl. 1), 17–20 (1991).
  PubMed Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia. Blood 92, 1541–1548 (1998).
• Talpaz, M. Interferon-α-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. Semin. Hematol. 38, 22–27 (2001).
  CAS PubMed Google Scholar
• Bonifazi, F. et al. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood 98, 3074–3081 (2001).
  CAS PubMed Google Scholar
• Borden, E. C. in Cancer Medicine 7 (eds Kufe, D. W. et al.) 733–743 (BC Decker, Ontario, 2006). An expanse on the clinical effectiveness of IFNs in both haematological malignancies and solid tumours. Complete text at http://ncbi.nlm.nih.gov/books .
  Google Scholar
• Rohatiner, A. Z. et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J. Clin. Oncol. 23, 2215–2223 (2005).
  CAS PubMed Google Scholar
• Gresser, I., Maury, C. & Belardelli, F. Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. VI. Adjuvant therapy after surgery in the inhibition of liver and spleen metastases. Int. J. Cancer 39, 789–792 (1987).
  CAS PubMed Google Scholar
• Müller, C. R., Smeland, S., Bauer, H. C., Saeter, G. & Strander, H. Interferon-α as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol. 44, 475–480 (2005).
  PubMed Google Scholar
• Kirkwood, J. M. et al. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10, 1670–1677 (2004).
  CAS PubMed Google Scholar
• Wheatley, K. et al. Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat. Rev. 29, 241–252 (2003).
  CAS PubMed Google Scholar
• Eggermont, A. M. M. & Gore, M. Randomized adjuvant therapy trials in melanoma: surgical and systemic trials. Semin. Oncol. 34, 507–513 (2007).
  Google Scholar
• Weiss, K. Safety profile of interferon-α therapy. Semin. Oncol. 25, S9–S13 (1998).
  Google Scholar
• Kirkwood, J. M. et al. Mechanisms and management of toxicities associated with high-dose interferon α-2b therapy. J. Clin. Oncol. 20, 3703–3718 (2002).
  CAS PubMed Google Scholar
• Diaz, M. O. et al. Deletions of interferon genes in acute lymphoblastic leukemia. N. Engl. J. Med. 322, 77–82 (1990).
  CAS PubMed Google Scholar
• Fountain, J. W. et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. Natl Acad. Sci. USA 89, 10557–10561 (1992).
  CAS PubMed Google Scholar
• Olopade, O. I. et al. Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res. 53 (Suppl. 10), 2410–2415 (1993).
  CAS PubMed Google Scholar
• DeYoung, K. L. et al. Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene 15, 453–457 (1997).
  CAS PubMed Google Scholar
• Ding, Y., Lee, J. F., Lu, H., Lee, M. H. & Yan, D. H. Interferon-inducible protein IFIXα1 functions as a negative regulator of HDM2. Mol. Cell Biol. 26, 1979–1996 (2006).
  CAS PubMed PubMed Central Google Scholar
• Johnsen, A., France, J., Sy, M. S. & Harding, C. V. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res. 58, 3660–3667 (1998).
  CAS PubMed Google Scholar
• Shou, J. et al. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc. Natl Acad. Sci. USA 99, 2830–2835 (2002).
  CAS PubMed Google Scholar
• Seliger, B. et al. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin. Cancer Res. 9, 1721–1727 (2003).
  CAS PubMed Google Scholar
• Hoek, K. et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 64, 5270–5282 (2004). Points to the potential role of suppression of constitutive of ISG expression, possibly by promoter methylation in the evolution of cell transformation.
  CAS PubMed Google Scholar
• Pitha-Rowe, I. et al. Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res. 64, 8109–8115 (2004).
  CAS PubMed Google Scholar
• Ito, N. et al. STAT3 polymorphism predicts interferon-α response in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 25, 2785–2791 (2007).
  CAS PubMed Google Scholar
• Casey, G. et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nature Genet. 32, 581–583 (2002). Describes a mutated ISG that results in predisposition to malignancy.
  CAS PubMed Google Scholar
• Borden, E. C. Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma. Cytokine Growth Factor Rev. 18, 491–501 (2007).
  CAS PubMed PubMed Central Google Scholar
• Nakaii, M. et al. IFN-α prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis 25, 389–397 (2004).
  Google Scholar
• Borden, E. C., Sidky, Y. A., Ertürk, E., Wierenga, W. & Bryan, G. T. Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine. Cancer Res. 50, 1071–1074 (1990). A preclinical example of the potential for IFNs or inducers to treat high-risk individuals.
  CAS PubMed Google Scholar
• Kulik, L. M. Can therapy of hepatitis C affect the development of hepatocellular carcinoma? J. Natl Comp. Cancer Netw. 4, 751–757 (2006).
  Google Scholar
• Chawla-Sarkar, M. et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8, 237–249 (2003).
  CAS PubMed Google Scholar
• Ballestrero, A. et al. Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells. Clin. Cancer Res. 10, 1463–1470 (2004).
  CAS PubMed Google Scholar
• Sato, K. et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-α/β. Eur. J. Immunol. 31, 3138–3146 (2001).
  CAS PubMed Google Scholar
• Chaperot, L. et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J. Immunol. 176, 248–255 (2006).
  CAS PubMed Google Scholar
• Buechner, S. A. et al. Regression of basal cell carcinoma by intralesional interferon-α treatment is mediated by CD95 (Apo-1/Fas)-CD95ligand-induced suicide. J. Clin. Invest. 100, 2691–2696 (1997).
  CAS PubMed PubMed Central Google Scholar
• Ugurel, S. et al. Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with Bcl-2 and Bcl-x expression and is sensitive to modulation by interferon-γ. Int. J. Cancer 82, 727–736 (1999).
  CAS PubMed Google Scholar
• Schwartzberg, L. S. et al. Modulation of the Fas signaling pathway by IFN-γ in therapy of colon cancer: Phase I trial and correlative studies of IFN-γ, 5-fluorouracil, and leukovorin. Clin. Cancer. Res. 8, 2488–2498 (2002).
  CAS PubMed Google Scholar
• Leaman, D. W. et al. Identification of X-linked inhibitor of apoptosis-associated factor-1 (XAF1) as an interferon-stimulated gene that augments TRAIL/Apo2L-induced apoptosis. J. Biol. Chem. 277, 28504–28511 (2002).
  CAS PubMed Google Scholar
• Lee, M. G. et al. Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses. Oncogene 25, 5807–5822 (2006).
  CAS PubMed Google Scholar
• Pizzoferrato, E. et al. Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Res. 64, 8381–8388 (2004).
  CAS PubMed Google Scholar
• Pfeffer, L. M. et al. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 58, 2489–2499 (1998). A complementary review to this one.
  CAS PubMed Google Scholar
• Tannenbaum, C. S. & Hamilton, T. A. Immune-inflammatory mechanisms in IFN-γ-mediated anti-tumor activity. Semin. Cancer Biol. 10, 113–123 (2000). A review of the immunoregulatory effects of IFNs.
  CAS PubMed Google Scholar
• Glimcher, L. H., Townsend, M. J., Sullivan, B. M. & Lord, G. M. Recent developments in the transcriptional regulation of cytolytic effector cells. Nature Rev. Immunol. 4, 900–911 (2004).
  CAS Google Scholar
• Mikhak, Z. et al. STAT1 in peripheral tissue differentially regulates homing of antigen-specific Th1 and Th2 cells. J. Immunol. 176, 4959–4967 (2006).
  CAS PubMed Google Scholar
• Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nature Rev. Immunol. 6, 836–848 (2006). Another excellent and complimentary review of the immunoregulatory effects of IFNs.
  CAS Google Scholar
• Swann, J. B. et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor functions. J. Immunol. 178, 7540–7549 (2007).
  CAS PubMed Google Scholar
• Strehl, B. et al. Interferon-γ, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol. Rev. 207, 19–30 (2005).
  CAS PubMed Google Scholar
• Greiner, J. W. et al. Intraperitoneal administration of interferon-γ to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J. Clin. Oncol. 10, 735–746 (1992).
  CAS PubMed Google Scholar
• Folkman, J. Angiogenesis: an organizing principle for drug discovery. Nature Rev. Drug Discovery 6, 273–286 (2007).
  CAS Google Scholar
• Brouty-Boye, D. & Zetter, B. R. Inhibition of cell motility by interferons. Science 208, 516–518 (1980).
  CAS PubMed Google Scholar
• Dvorak, H. F. & Gresser, I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J. Natl Cancer Inst. 81, 497–502 (1989).
  CAS PubMed Google Scholar
• Sidky, Y. A. & Borden, E. C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 47, 5155–5161 (1987).
  CAS PubMed Google Scholar
• Dinney, C. P. et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res. 58, 808–814 (1998).
  CAS PubMed Google Scholar
• McCarty, M. F., Bielenberg, D., Donawho, C., Bucana, C. D. & Fidler, I. J. Evidence for the causal role of endogenous interferon-α/β in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin. Exp. Metastasis 19, 609–615 (2002). A review emphasizing the potential role of antiangiogenic effects of IFNs.
  CAS PubMed Google Scholar
• von Marschall, Z. et al. Effects of interferon α on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl Cancer Inst. 95, 437–448 (2003).
  CAS PubMed Google Scholar
• Reznikov, L. L. et al. Spontaneous and inducible cytokine responses in healthy humans receiving a single dose of IFN-α2b: increased production of interleukin-1 receptor antagonist and suppression of IL-1-induced IL-8. J. Interferon Cytokine Res. 18, 897–903 (1998).
  CAS PubMed Google Scholar
• Yang, J. & Richmond, A. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol. Ther. 9, 846–855 (2004).
  CAS PubMed PubMed Central Google Scholar
• Feldman, E. D. et al. Interferon γ-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann. Surg. Oncol. 13, 125–133 (2006).
  PubMed Google Scholar
• Guenzi, E. et al. The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO J. 22, 3772–3782 (2003).
  CAS PubMed PubMed Central Google Scholar
• Lindner, D. J. Interferons as antiangiogenic agents. Curr. Oncol. Rep. 4, 510–514 (2002).
  Google Scholar
• Faria, A. M. et al. The nucleoporin Nup96 is required for proper expression of interferon-regulated proteins and functions. Immunity 24, 295–304 (2006).
  CAS PubMed Google Scholar
• Han, J. Q. & Barton, D. J. Activation and evasion of the antiviral 2′-5′ oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA 8, 512–525 (2002).
  CAS PubMed PubMed Central Google Scholar
• Gale, M. J. Jr et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230, 217–227 (1997).
  CAS PubMed Google Scholar
• Carpten, J. et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nature Genet. 30, 181–184 (2002).
  CAS PubMed Google Scholar
• Urisman, A. et al. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2, e25 (2006).
  PubMed PubMed Central Google Scholar
• Dong, B. et al. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc. Natl Acad. Sci. USA 104, 1655–1660 (2007).
  CAS PubMed Google Scholar
• Pedersen, I. M. et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449, 919–922 (2007).
  CAS PubMed PubMed Central Google Scholar
• Brideau-Andersen, A. D. et al. Directed evolution of gene-shuffled IFN-α molecules with activity profiles tailored for treatment of chronic viral diseases. Proc. Natl Acad. Sci. USA 104, 8269–8274 (2007).
  CAS PubMed Google Scholar
• Walsh, R. J. et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 56, 3784–3792 (2007).
  CAS PubMed PubMed Central Google Scholar